Cart
sales@molnova.com
Secoisolariciresinol b
CAS No. 145265-02-7
Secoisolariciresinol b( ——— )
Catalog No. M38400 CAS No. 145265-02-7
(+)-Secoisolariciresinol, a lignan compound, is a (+)-enantiomer of Secoisolariciresinol.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 140 | In Stock |
|
| 10MG | 242 | In Stock |
|
| 25MG | 410 | In Stock |
|
| 50MG | 594 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSecoisolariciresinol b
-
NoteResearch use only, not for human use.
-
Brief Description(+)-Secoisolariciresinol, a lignan compound, is a (+)-enantiomer of Secoisolariciresinol.
-
Description(+)-Secoisolariciresinol, a lignan compound, is a (+)-enantiomer of Secoisolariciresinol.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number145265-02-7
-
Formula Weight362.42
-
Molecular FormulaC20H26O6
-
Purity>98% (HPLC)
-
SolubilityDMSO : 50 mg/mL (137.96 mM; ultraphonic )
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shiro Suzuki, et al. Stereochemical diversity in lignan biosynthesis of Arctium lappa L. Biosci Biotechnol Biochem. 2002 Jun;66(6):1262-9.?
molnova catalog
related products
-
Lys-(Hyp3)-Bradykini...
Lys-[Hyp3]-Bradykinin a Bradykinin agonist. Lys-[Hyp3]-Bradykinin is a kinin, it can be isolated from human urine. Lys-[Hyp3]-Bradykinin can be used for the research of inflammation.
-
Angelic anhydride
Angelic Anhydride is a reagent in the improved synthesis of angelate esters, which are the active chemical behind the strong pain-relieving and spasmolytic action of extracts from the plant butterbur.
-
MRT-2359
MRT-2359 is a potent and orally available GSPT1 reducer with antitumour activity.MRT-2359 inhibits the growth of drug-resistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.MRT-2359 exhibits preferential activity in MYC-driven cell lines.
